Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, ...
RAS genes are the second most frequently mutated genes in cancer, and mutant RAS proteins are key drivers of some of the deadliest cancers, including nearly all pancreatic cancers, half of ...
Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and helped explain how it promotes tumor growth. In this new study, the ...
For instance, growth-promoting genes, such as the gene for the signaling protein Ras, are among those most commonly mutated in cancer cells, becoming super-active and producing cells that are too ...
We discovered one of the major ways by which RAS oncogenes cause normal cells to become cancerous – and identified new targets for cancer treatment. Scientists at The Institute of Cancer Research led ...
Historically, scientists in the division were the first to make the ground-breaking discovery of the mechanism by which the RAS gene – one of the most commonly activated genes in cancer – causes cells ...
Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and ...
It causes mutations in the p53 tumor-suppressor gene as well as ras mutations ... They state, "In lung cancer p53 mutations have been found in 56% of tissue samples, and in colorectal, esophageal ...
“Colorectal-cancer researchers have waited nearly a ... namely those who have a non-mutated version of the RAS gene, panitumumab or bevacizumab combined with chemotherapy are treatment options.
Although many of the genes involved in cancer have now been identified ... small GTPase proteins and are mutated in lung adenocarcinoma and in the germline of “Ras-opathy” patients. Although KRAS has ...
The candidate, dubbed onvansertib, is being tested among patients with first-line RAS-mutated metastatic ... patients with non-small cell lung cancer and a genetic mutation dubbed KRAS G12C ...